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Background
In a case-controlled analysis designed to identify immune
correlates of infection risk in the RV144 HIV vaccine trial,
2/6 primary variables showed significant correlation. One,
the binding of IgG antibodies to the V1/V2 loop of HIV-1
env protein appears to protect against HIV-1 infection.
Consequently, data from a detailed mapping of antibody
reactivities in response to vaccination on a sub-protein
level might be a predictor for vaccine efficacy. In contrast
to assays relying on whole antigens, peptide microarrays
are efficient tools to deliver such information. Besides,
complex peptide libraries can cover the HIV sequence
diversity. We present peptide microarray data from a
human clinical trial.
Methods
A library representing Env-gp160 consensus sequences
from clades A,B,C,D,M,CRF1, and CRF2 was produced.
Serum samples of vaccinees from groups receiving differ-
ent doses of a prototype Ad26 vector-based vaccine
expressing clade A-HIV-1 Env (Ad26.EnvA.01) were eval-
uated. For the calculation of signals the signal intensity per
peptide at baseline was substracted from the signal inten-
sity at week 28 after vaccination.
Results
All groups of vaccinees show a clear pattern of antibody
reactivity after vaccination. This pattern depends on the
dose and the number of doses given. From the lowest
doses of 1x109 viral particles (vp) a cross-clade reactivity
towards the V3 region of gp120 is observed. At doses
above 1x1010 vp the magnitude of signals is enhanced and
new regions of gp120 are targeted by patient antibodies,
e.g. towards the V2 loop region. The representation of
different clades on the peptide microarray allows for a
detailed investigation of the clade specificity of the anti-
body response after vaccination.
Conclusion
Costly vaccination studies require consideration of all pos-
sible factors for success. The results of peptide microarray
experiments may facilitate the design and dosing regimen
of vaccines in clinical trials and shed light on the underly-
ing protective mechanisms.
Author details
1JPT Peptide Technologies, Berlin, Germany. 2Div. of Vaccine Res., Beth Israel
Deaconess Medical Center, HMS, Boston, MA, USA. 3Crucell Holland BV,
Leiden, the Netherlands.
Published: 13 September 2012
doi:10.1186/1742-4690-9-S2-P95
Cite this article as: Reimer et al.: Humoral immune response profiling
with peptide microarrays. Retrovirology 2012 9(Suppl 2):P95.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit1JPT Peptide Technologies, Berlin, Germany
Full list of author information is available at the end of the article
Reimer et al. Retrovirology 2012, 9(Suppl 2):P95
http://www.retrovirology.com/content/9/S2/P95
© 2012 Reimer et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
